Articles related to MYELOMA

Discover how a recent class-action lawsuit against Bristol Myers Squibb could impact the availability and cost of multiple myeloma treatment options.

Discover how Elrexfio’s conditional FDA approval could redefine the treatment landscape for patients with difficult-to-treat multiple myeloma. Dive into the promising clinical trial results and understand its potential impact on your practice.

This Phase 1-2 study presents compelling evidence for the efficacy of mezigdomide in combination with dexamethasone for patients with relapsed and refractory multiple myeloma. Explore the study to understand how this novel treatment could eventually fit into your therapeutic strategy.

The FDA’s accelerated approval of elranatamab offers a new therapeutic pathway for adults with relapsed or refractory multiple myeloma. With promising response rates and an established safety profile, this treatment may provide a much-needed option for those struggling with relapsed myeloma.

The recent study by Roswell Park Comprehensive Cancer Center demonstrates that exercise may significantly impact the immune system in multiple myeloma patients. Explore the potential of this nonpharmaceutical approach to enhance immune function and provide a new avenue for controlling this blood cancer.

The phase 3 study evaluating cilta-cel, a BCMA–directed CAR T-cell therapy, in patients with lenalidomide-refractory multiple myeloma indicates promising results in progression-free survival and overall response rates.